Mirati Therapeutics

Cancer is unique. Cancer is smart. Cancer is specific. Treatment should be too. Mirati is at the forefront of precision medicine -- developing genetically-targeted oncology therapeutics for carefully selected groups of patients most likely to benefit from treatment. Mirati’s approach to precision medicine combines three critical factors. Most importantly, Mirati’s drug candidates target specific genetic and epigenetic drivers of cancer. Mirati combines the therapeutic potential of these assets with its creative and agile clinical development strategies focused on identifying and treating patients whose tumors carry the drivers of disease. Finally, this process is led and executed by a highly accomplished precision medicine team, with a track record of bringing breakthrough therapies with accelerated development paths to market.

Type

Public

San Diego, US

Size (employees)

38 (est)

Website

mirati.com

Mirati Therapeutics is headquartered in San Diego, US

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego

San Diego, US (HQ)

200 9393 Towne Centre Dr

Mirati Therapeutics Data and Metrics

Mirati Therapeutics Financial Metrics

Summary

USD

Mirati Therapeutics's current market capitalization is $118.3 m.

Income Statement

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
R&D expense				68.5 m
General and administrative expense				15.3 m
Operating expense total	32 m	39.1 m	64.7 m	83.8 m
EBIT	(32 m)	(39.1 m)	(64.7 m)	(83.8 m)
Pre tax profit	(52.9 m)	(43.7 m)	(64.5 m)	(83.1 m)
Income tax expense	(23 k)
Net Income	(52.9 m)	(43.7 m)	(64.5 m)	(83.1 m)

Balance Sheet

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	14.2 m	6.6 m	49.5 m	22.4 m
Current Assets	64.2 m	32.7 m	125.4 m	59.6 m
PP&E	322 k	496 k	614 k	629 k
Total Assets	64.5 m	33.5 m	128 m	63.4 m
Accounts Payable				15 m
Current Liabilities	38.7 m	5.4 m	9.8 m	15 m
Additional Paid-in Capital	214.8 m	260.6 m	415.2 m	428.5 m
Retained Earnings	(198.4 m)	(242.1 m)	(306.6 m)	(389.8 m)
Total Equity	25.9 m	28.1 m	118.2 m	48.3 m
Financial Leverage	2.5 x	1.2 x	1.1 x	1.3 x

Cash Flow

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income		(43.7 m)	(64.5 m)	(83.1 m)
Depreciation and Amortization	171 k	199 k	212 k	180 k
Cash From Operating Activities			(50.7 m)	(68 m)
Purchases of PP&E	(204 k)	(386 k)	(329 k)	(196 k)
Income Taxes Paid	35 k